Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Flexicath raises $600,000 in financing, wins clearance for new catheter
The funding will be used to ramp-up US and international sales and marketing for the FirmGrip catheter. The patent pending Flexicath FirmGrip is said to be designed to
The funding will be used to ramp-up US and international sales and marketing for the FirmGrip catheter. The patent pending Flexicath FirmGrip is said to be designed to
According to Neelie Kroes, the European competition commissioner, the drug makers have resorted to two main tactics to delay the availability of the low-cost medicines. They have either
Under the terms of the letter of intent, Sigma-Tau has purchased $1.5 million of Dor’s common stock at the market price of $0.09 per share, which will be
Priority review is granted by the FDA for a treatment that addresses a significant unmet medical need. A Prescription Drug User Fee Act target date of April 2,
The agreement makes Cardinal Health the exclusive manufacturer of SRI Surgical’s complete line of more than 400 disposable surgical kits. In addition, the agreement provides for the development
The marketing authorization application (MAA) for Cerepro, filed following a pre-submission meeting with the European medicines regulatory agency (EMEA), will now enter the validation stage, prior to commencing
Advanced Cell Technology (ACTC) will exclusively license to the joint venture, which will be majority owned by CHA, all of its hemangioblast technology. CHA will contribute working capital
The cethromycin new drug application (NDA) is based on a full clinical development and manufacturing program for cethromycin. The program included two global Phase III pivotal studies for
Under the terms of the agreement, Novozymes Biopharma will exclusively supply its recombinant human albumin, Recombumin, for the continued development and commercialization of ConjuChem’s PC-DAC:Exendin-4. The agreement calls
Neat is said to be a versatile genomics testing platform that enables gene-controlled ligation of oligonucleotide probes inside of cells. This highly specific technique will be used to